SAN DIEGO

圣迭戈

,

，

Oct. 8, 2026

2026年10月8日

/PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq:

/美通社/ -- Atrium Therapeutics, Inc.（纳斯达克：

RNA

核糖核酸

) ('Atrium' or the 'Company'), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that it has entered into a securities purchase agreement (the 'purchase agreement') with a group of leading institutional investors for a private placement financing (the 'private placement').

)（“Atrium”或“公司”），一家通过开发靶向心脏的RNA疗法来推进精准心脏病学的生物制药公司，今日宣布已与一组领先的机构投资者签订证券购买协议（“购买协议”），以进行私募配售融资（“私募配售”）。

The private placement is expected to result in aggregate gross proceeds to the Company of approximately $50 million, before deducting placement agent fees and other offering expenses..

预计本次私募配售将为本公司带来约5,000万美元的总募集资金，未扣除配售代理费及其他发行费用。

The private placement includes participation from Sirenia Capital Management LP, Aberdeen Investments, Montanova, Sessa Capital, Casdin Capital, a life sciences-focused institutional investor and others.

本次私募配售的参与方包括Sirenia Capital Management LP、Aberdeen Investments、Montanova、Sessa Capital、Casdin Capital、一家专注于生命科学的机构投资者以及其他投资者。

Pursuant to the terms of the purchase agreement, the Company agreed to issue and sell an aggregate of (i) 5,170,384 shares of its common stock, at a price of $7.93 per share, and (ii)  pre-funded warrants to purchase up to 1,134,930 shares of common stock, at a price of $7.929 per pre-funded warrant, which equals the per share price of $7.93 less the exercise price $0.001 for such pre-funded warrant.

根据购买协议的条款，公司同意发行并出售总计（i）5,170,384股普通股，每股价格为7.93美元；以及（ii）最多可购买1,134,930股普通股的预融资认股权证，每份预融资认股权证的价格为7.929美元，即每股价格7.93美元减去该预融资认股权证的行权价0.001美元。

The pre-funded warrants are immediately exercisable and will expire when exercised in full. The private placement was priced at-the-market under the rules of The Nasdaq Stock Market LLC. The private placement is expected to close on or about October 9, 2026, subject to the satisfaction of customary closing conditions..

预融资认股权证可立即行权，并将在全部行权时到期。根据纳斯达克股票市场有限责任公司的规则，此次私募配售按市价定价。在满足惯常交割条件的前提下，预计此次私募配售将于2026年10月9日或前后完成交割。

The Company intends to use the net proceeds from the private placement, together with its current cash, cash equivalents and investments, to fund development of its two lead product candidates, other research programs, working capital and general corporate purposes. The Company estimates that the net proceeds from the private placement together with existing cash, cash equivalents and investments, will fund its operations through 2028..

本公司拟将私募配售所得款项净额，连同其现有现金、现金等价物及投资，用于资助其两个领先候选产品的开发、其他研究项目、营运资金及一般公司用途。本公司估计，私募配售所得款项净额连同现有现金、现金等价物及投资，将足以支持其运营至2028年。

Leerink Partners acted as lead placement agent for the private placement. Cantor, Barclays and Wells Fargo Securities acted as placement agents for the private placement.

Leerink Partners 担任此次私募发行的牵头配售代理。Cantor、Barclays 和 Wells Fargo Securities 担任此次私募发行的配售代理。

The securities to be sold in the private placement have not been registered under the Securities Act of 1933, as amended (the 'Securities Act'), or any state or other applicable jurisdiction's securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions' securities laws.

本次私募配售中拟出售的证券未根据经修订的《1933年证券法》（以下简称“《证券法》”）或任何州或其他适用司法管辖区的证券法律进行注册，且除非已办理注册手续或符合《证券法》及适用州或其他司法管辖区证券法律规定的注册豁免条件，否则不得在美国境内进行要约或销售。

Concurrently with entering into the purchase agreement, the Company and the investors entered into a registration rights agreement pursuant to which the Company has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock and the shares of common stock issuable upon the exercise of the pre-funded warrants issued in the private placement..

在与签署购买协议的同时，公司与投资者签订了一份注册权协议，根据该协议，公司已同意向美国证券交易委员会提交一份注册声明，以注册普通股股份的转售以及因行使在私募中发行的预付认股权证而可发行的普通股股份。

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction..

本新闻稿不构成出售任何证券的要约，也不构成购买任何证券的要约邀请；在任何州或其他司法管辖区，若根据该州或其他司法管辖区的证券法律，在注册或资格认定之前进行此类要约、邀请或销售属于违法行为，则不得在该等地进行此类要约、邀请或销售。

About Atrium Therapeutics

关于Atrium Therapeutics

Atrium Therapeutics, Inc. (Nasdaq:

Atrium Therapeutics, Inc.（纳斯达克：

RNA

核糖核酸

) is pioneering targeted delivery of ribonucleic acid (RNA) therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. With the U.S. Food and Drug Administration's (FDA)  clearance of its Investigational New Drug (IND) application for ATR 1072 for PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome, Atrium is advancing its first precision cardiology program into the clinic through the Corventis Phase 1/2 clinical trial.

）正在开创性地将核糖核酸（RNA）疗法靶向递送至心脏，以改变心肌病患者的护理标准。随着美国食品药品监督管理局（FDA）批准其针对PRKAG2（AMP激活的非催化亚基Gamma 2蛋白激酶）综合征的ATR 1072研究新药（IND）申请，Atrium公司正通过Corventis一期/二期临床试验将其首个精准心脏病学项目推进至临床阶段。

The Company's proprietary technology - designed at Avidity Biosciences, Inc. - combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with the precision of oligonucleotides, and is designed to selectively target the underlying drivers of genetically driven cardiac diseases through targeted, non-viral delivery of small interfering RNA (siRNA).

该公司的专有技术由 Avidity Biosciences, Inc. 设计，将单克隆抗体（mAbs）及其他靶向递送配体的组织选择性与寡核苷酸的精确性相结合，旨在通过小干扰 RNA（siRNA）的靶向非病毒递送，选择性靶向遗传性心脏疾病的根本驱动因素。

This approach builds upon learnings from demonstrated delivery to skeletal muscle and applies it for efficient delivery to the heart, with the potential to overcome challenges associated with non-specific tissue delivery. Beyond ATR 1072, the Company's pipeline includes ATR 1086 for PLN (phospholamban) cardiomyopathy and two undisclosed research targets in rare cardiomyopathies..

该方法基于在骨骼肌递送方面已验证的经验，并将其应用于心脏的高效递送，有望克服与非特异性组织递送相关的挑战。除ATR 1072外，公司的产品管线还包括用于PLN（磷脂兰宾）心肌病的ATR 1086，以及两个针对罕见心肌病的未公开研究靶点。

Forward-Looking Statements

前瞻性陈述

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as 'potential,' 'can,' 'will,' 'plan,' 'may,' 'could,' 'would,' 'expect,' 'anticipate,' 'look forward,' 'believe,' 'committed,' 'investigational,' 'pipeline,' 'launch,' or similar terms, or by express or implied discussions regarding Atrium Therapeutics' ('Atrium's' or 'our') future results of operations and financial condition.

本新闻稿包含经1995年美国《私人证券诉讼改革法案》界定的前瞻性陈述。前瞻性陈述通常可通过“潜在”、“能够”、“将”、“计划”、“可能”、“可以”、“会”、“预期”、“预计”、“展望”、“相信”、“致力于”、“研究性”、“管线”、“推出”等词语或类似术语，或通过明示或暗示地讨论Atrium Therapeutics（“Atrium”或“我们”）未来的经营业绩和财务状况来识别。

Specifically, this press release contains forward-looking information relating the completion of the private placement on the anticipated terms, timing or at all; the anticipated use of the proceeds from the private placement; and our expected cash runway and the period over which existing cash, cash equivalents and investments are expected to fund planned operations.

具体而言，本新闻稿包含涉及以下方面的前瞻性信息：非公开发行能否按预期条款、时间完成或是否根本完成；非公开发行所得款项的预期用途；以及我们预期的现金跑道，即现有现金、现金等价物和投资预计为计划中的运营提供资金的期间。

Such forward-looking statements are based on management's current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Particular areas where risks or uncertainties could cause our actual results to be materially different than those expressed in our forward-looking statements include but are not limited to: our ability to satisfy the closing conditions for the private placement, the initiation, timing, progress, potential registrational quality, and results of our research and development programs, preclinical studies, any clinical trials, and other regulatory submissions; the potential for clinical trial results to differ from our preclinical studies; our ability to timely enroll a sufficient number of patients in our clinical trials, such as Corventis; the beneficial characteristics, including poten.

此类前瞻性陈述基于管理层对当前未来事件的信念和预期，并受到重大已知和未知风险及不确定性的影响。可能导致我们的实际结果与前瞻性陈述中表达的结果存在重大差异的风险或不确定性领域包括但不限于：我们满足私募配售交割条件的能力；研发项目、临床前研究、任何临床试验及其他监管申报的启动、时间安排、进展、潜在的注册质量及结果；临床试验结果可能与我们的临床前研究存在差异的可能性；我们及时在临床试验（如Corventis）中招募足够数量患者的能力；其有益特性，包括潜力。

www.sec.gov

www.sec.gov

. Atrium is providing the information in this communication as of this date and does not undertake any obligation to update any forward-looking statements contained in this communication as a result of new information, future events or otherwise, except as required by law.

Atrium 仅按本沟通文件发布之日提供相关信息，除非法律另有要求，否则不承担因新信息、未来事件或其他原因而更新本沟通文件中任何前瞻性陈述的义务。

SOURCE Atrium Therapeutics

来源：Atrium Therapeutics

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示